China's healthcare sector sees record US$10.6 billion fundraising as biotech booms

China's healthcare sector is on track to secure record fundraising this year, driven by robust global investor demand and growth momentum, according to analysts. Several Chinese biopharmaceutical companies have tapped equity capital markets - mainly in Hong Kong - for initial public offerings (IPOs), follow-on deals and block share placements this year. Year to date, the fundraising reached US$10.6 billion (HK$82.5 billion), more than the combined total from 2022 to 2024, according to Dealogic data. Do ...